Landos Biopharma’s Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays and Costs

Landos Biopharma, Inc. (LABP) has disclosed a new risk, in the Regulation category.

Landos Biopharma, Inc. faces significant regulatory hurdles in its impending transaction, with approvals contingent on adherence to the HSR Act and other regulatory endorsements. Scrutiny from the FTC and analogous agencies, focused on maintaining competitive markets, might lead to conditional approvals imposing stringent requirements or costly concessions. Such impositions could introduce substantial delays, inflate expenses, or, in extreme cases, prompt the parties to forsake the deal entirely if compliance proves too burdensome or detrimental to projected outcomes.

Overall, Wall Street has a Hold consensus rating on LABP stock based on 2 Holds.

To learn more about Landos Biopharma, Inc.’s risk factors, click here.